Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement

Journal of Bone and Joint Surgery - Series B

Volumn 89, Issue 2, 2007, Pages 155-159

  Saudan, Marc ^a   Saudan, P ^a   Perneger, T ^a   Riand, N ^a   Keller, A ^a   Hoffmeyer, P ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CELECOXIB; CREATININE; IBUPROFEN; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANALGESIA; ANTERIOR POSTERIOR AXIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG WITHDRAWAL; DUODENUM ULCER; ELECTROLYTE DISTURBANCE; ESOPHAGUS ULCER; FEMALE; GASTROINTESTINAL SYMPTOM; HETEROTOPIC OSSIFICATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PAIN; PELVIS RADIOGRAPHY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; STOMACH ULCER; TOTAL HIP PROSTHESIS; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; OSSIFICATION, HETEROTOPIC; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; PYRAZOLES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; SULFONAMIDES;

EID: 33947246146     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.89B2.17747     Document Type: Article

References (28)

1. Ahrengart L. Periarticular heterotopic ossification after total hip arthroplasty: risk factors and consequences. Clin Orthop 1991;263:49-58.
2. Barthel T, Baumann B, Noth U, Eulert J. Prophylaxis of heterotopic ossification after total hip arthroplasty: a prospective randomized study comparing indomethacin and meloxicam. Acta Orthop Scand 2002;73:611-14.
3. Brooker AF, Bowerman JW, Robinson RA, Riley LH Jr. Ectopic ossification following total hip replacement: incidence and a method of classification. J Bone Joint Surg [Am] 1973;55-A:1629-32.
4. Cella JP, Salvati EA, Sculco TP. Indomethacin for the prevention of heterotopic ossification following total hip arthroplasty: effectiveness, contra indications, and adverse effects. J Arthroplasty 1988;3:229-34.
5. Neal B. Effects of heterotopic bone formation on outcome after hip arthroplasty. ANZ J Surg 2003;73:422-6.
6. Eggli S, Rodriguez J, Ganz R. Heterotopic ossification in total hip arthroplasty: the significance for clinical outcome. Acta Orthop Belg 2000;66:174-80.
7. Knelles D, Barthel T, Karrer A, et al. Prevention of heterotopic ossification after total hip replacement: a prospective, randomised study using acetylsalicylic acid, indomethacin and fractional or single-dose irradiation. J Bone Joint Surg [Br] 1997;79-B:596-602.
8. Pagnani MJ, Pellicci PM, Salvati EA. Effect of aspirin on heterotopic ossification after total hip arthroplasty in men who have osteoarthrosis. J Bone Joint Surg [Am] 1991;73-A:924-9.
9. Neal BC, Rodgers A, Gray H, et al. No effect of low-dose aspirin for the prevention of heterotopic bone formation after total hip replacement: a randomized trial of 2,649 patients. Acta Orthop Scand 2000;71:129-34.
10. Dahl H. Kliniske observajoner. In: Symposium about hip arthrosis. 1974.
11. Hitter MA, Sieber JM. Prophylactic indomethacin for the prevention of heterotopic bone formation following total hip arthroplasty. Clin Orthop 1985;196:217-25.
12. Schmidt SA, Kjaersgaard-Andersen P, Pederson NW, et al. The use of indomethacin to prevent the formation of heterotopic bone after total hip replacement: a randomized, double-blind clinical trial. J Bone Joint Surg [Am] 1988;70-A:834-8.
13. Elmstedt E, Lindholm TS, Nilsson OS, Tornkvist H. Effect of ibuprofen on heterotopic ossification after hip replacement. Acta Orthop Scand 1985;56:25-7.
14. Persson PE, Sodemann B, Nilsson OS. Preventive effects of ibuprofen an periarticular heterotopic ossification after total hip arthroplasty: a randomised double-blind prospective study of treatment time. Acta Orthop Scand 1998;69:111-15.
15. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. Faseb J 1998;12:1063-73.
16. Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996;25:373-96.
17. Greenberg HE, Gottesdiener K, Huntington M, et al. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol 2000;40:1509-15.
18. Reuben SS, Fingeroth R, Krushell R, et al. Evaluation of safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty. J Arthroplasty 2002;17:26-31.
19. Juni P, Nartey L, Reichenbach S, Sterchi R, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analaysis. Lancet 2004,364:2021-9.
20. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
21. Oviedo JA, Schroy PC 3rd. Does celecoxib use increase the risk of cardiovascular events? Gastroenterology 2005;129:1348-50.
22. Bhattacharyya T, Smith RM. Cardiovascular risks of coxibs: the orthopaedic perspective. J Bone Joint Surg [Am]2005:87-A:245-6.
23. Simon AM, Manigrasso MB, O'Connor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002; 17:963-76.
24. Zhang X, Schwarz EM, Young DA, et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the obsteolblast lineage and is critically involved in bone repair. J Clin Invest 2002;109:1405-15.
25. Goodman S, Ma T, Trindade M, et al. COX-2 selective NSAID decreases bone ingrowth in vivo. J Orthop Res 2002;20:1164-9.
26. Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40:1109-20.
27. McMahon JS, Waddell JP, Morton J. Effect of short-course indomethacin on heterotopic bone formation after uncemented total hip arthroplasty. J Arthroplasty 1991;6:259-64.
28. Ritter MA, Vaughan RB. Ectopic ossification after total hip arthroplasty: predisposing factors, frequency, and effect on results. J Bone Joint Surg [Am] 1977;59-A:345-51.